Norges Bank Invests $300.79 Million in Insulet Corporation $PODD

Norges Bank bought a new position in shares of Insulet Corporation (NASDAQ:PODD) during the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor bought 1,058,238 shares of the medical instruments supplier’s stock, valued at approximately $300,794,000.

A number of other institutional investors also recently modified their holdings of the company. Vanguard Group Inc. raised its position in shares of Insulet by 1.0% during the third quarter. Vanguard Group Inc. now owns 8,796,200 shares of the medical instruments supplier’s stock worth $2,715,651,000 after purchasing an additional 87,845 shares during the period. Geode Capital Management LLC raised its position in Insulet by 2.1% in the 4th quarter. Geode Capital Management LLC now owns 2,006,413 shares of the medical instruments supplier’s stock valued at $568,274,000 after buying an additional 41,019 shares during the last quarter. Northern Trust Corp raised its position in Insulet by 0.5% in the 3rd quarter. Northern Trust Corp now owns 709,180 shares of the medical instruments supplier’s stock valued at $218,945,000 after buying an additional 3,618 shares during the last quarter. Qube Research & Technologies Ltd raised its position in Insulet by 37.3% in the 3rd quarter. Qube Research & Technologies Ltd now owns 574,365 shares of the medical instruments supplier’s stock valued at $177,324,000 after buying an additional 156,009 shares during the last quarter. Finally, Nordea Investment Management AB raised its position in Insulet by 35.0% in the 4th quarter. Nordea Investment Management AB now owns 551,133 shares of the medical instruments supplier’s stock valued at $157,128,000 after buying an additional 142,922 shares during the last quarter.

Wall Street Analysts Forecast Growth

A number of research firms recently commented on PODD. Benchmark reissued a “buy” rating on shares of Insulet in a research report on Wednesday, May 27th. Barclays lowered their price target on Insulet from $286.00 to $198.00 and set an “underweight” rating for the company in a research report on Thursday, May 7th. Oppenheimer lowered their price target on Insulet from $300.00 to $210.00 and set an “outperform” rating for the company in a research report on Thursday, May 7th. TD Cowen lowered their price target on Insulet from $379.00 to $294.00 and set a “hold” rating for the company in a research report on Monday. Finally, Weiss Ratings lowered Insulet from a “hold (c)” rating to a “hold (c-)” rating in a research report on Friday, May 15th. Twenty-one equities research analysts have rated the stock with a Buy rating, five have given a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, Insulet currently has an average rating of “Moderate Buy” and a consensus price target of $252.04.

Insulet Stock Down 3.8%

Shares of NASDAQ:PODD opened at $142.43 on Wednesday. The company has a market capitalization of $9.86 billion, a PE ratio of 33.12, a price-to-earnings-growth ratio of 1.17 and a beta of 1.13. The company has a debt-to-equity ratio of 0.71, a current ratio of 2.49 and a quick ratio of 1.81. The business has a fifty day moving average price of $181.94 and a two-hundred day moving average price of $243.52. Insulet Corporation has a 1 year low of $140.63 and a 1 year high of $354.88.

Insulet (NASDAQ:PODD) last announced its quarterly earnings data on Wednesday, May 6th. The medical instruments supplier reported $1.42 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.19 by $0.23. The firm had revenue of $761.70 million during the quarter, compared to the consensus estimate of $729.89 million. Insulet had a return on equity of 26.87% and a net margin of 10.44%.The business’s revenue for the quarter was up 33.9% on a year-over-year basis. During the same quarter in the prior year, the company earned $1.02 EPS. Insulet has set its FY 2026 guidance at 6.210- EPS. Analysts forecast that Insulet Corporation will post 6.44 earnings per share for the current year.

Insulet Profile

Insulet Corporation is a medical device company headquartered in Acton, Massachusetts, that develops, manufactures and sells insulin-delivery systems for people with diabetes. The company’s core business is the design and commercialization of its Omnipod family of tubeless, wearable insulin pumps and the consumable Pods that deliver insulin. Insulet’s products aim to simplify insulin delivery for people with type 1 diabetes and insulin-requiring type 2 diabetes by offering an alternative to traditional insulin pens and tethered pump systems.

The company’s product portfolio includes the Omnipod System line—disposable, waterproof Pods that adhere to the skin and deliver insulin—and the associated controllers and mobile applications used to program and monitor insulin delivery.